Biotech & Finance Forum, 29 November 2004, Barcelona
29 November 2004 - 29 November 2004
Spain
The Forum focuses on selecting the most innovative and promising private biotech, life sciences and med-tech companies and presenting them to an exclusive audience of Europe's leading life sciences and biotech investors and senior executives from top pharmaceutical companies.
Programme:,08.30 - 09.30: One2One meetings,Pre-booked meetings for presenting companies
09:35 - Welcome ,Christian Suojanen, Director Business Development, Europe Unlimited
09:45 - Keynote Speech,Thomas Bliss, Director International Licensing, Amgen
10:00 - Plenary Session "Biotech dealmaking in Europe",Moderator: Dr Fintan Walton, Chairman & CEO, PharmaVentures,Speakers:,Dr Margaret Beer, Director Scientific Liaison, Licensing & External Research Europe, Merck,Christine de los Reyes, Senior Director Licensing & Development, Pfizer,Brian Hargreaves, Global Sector Head, Healthcare, 3i,James Geraghty, Senior Vice President International Development, Genzyme,Dr Helmut Schühsler, Managing Partner, Techno Venture Management
11:45: Company Presentation Sessions (in parallel),21 Biotech CEOs present their business to an audience of international investors and 6 expert reviewers who will lead the Q&A
14:30 - Financial workshops (in parallel),Financing options for biotech companies beyond seed capital,The pro's and con's of various sources of finance. What are the arrays of financing possibilities available to biotech companies? Are some business models better suited to certain financing options than others? When is debt financing possible? Which provide sustainable financing rounds?....,Moderator:,Gordon Duncan, Dunhaw Capital,Speakers:,Brian Kerr, Director Healthcare & Life Sciences Group, Scottish Equity Partners,Carole Nuechterlein, Roche ,Philippe Guinot, Senior Partner, Crédit Lyonnais Private Equity
Cross Continental biotech deals,The different legal systems, registration systems as well as culture brings some unique problems with it. ,Moderator:,Yvonne E. Schlaeppi, Chair, International Practice, Palmer & Dodge LLP ,Speakers:,Hubert Birner, General Partner, Techno Venture Management,Stan Yakatan, Chairman, Katan Associates,Geoff McMillan, Chief Executive, Biofocus
Changing business models,When forced to adapt, how can and do companies make the transition from one business model to another?,Moderator: ,Morris Berrie, Editor in Chief, Biotechnology Investment Today,Speakers: ,Jörn Aldag, President & CEO, Evotec OAI,Raymond Spencer, CFO, Antisoma,Mike Ward, CoFounder & Director, Critical I
15:30 - Company Presentation Sessions (in parallel),21 Biotech CEOs present their business to an audience of international investors and 6 expert reviewers who will lead the Q&A
17:30 : Keynote Speech,David Flores, CEO & President, BioCentury
18:00 - 19:00: One2One meetings,Pre-booked meetings for presenting companies
For more information, please visit http://www.e-unlimited.com/bff(opens in new window)
Programme:,08.30 - 09.30: One2One meetings,Pre-booked meetings for presenting companies
09:35 - Welcome ,Christian Suojanen, Director Business Development, Europe Unlimited
09:45 - Keynote Speech,Thomas Bliss, Director International Licensing, Amgen
10:00 - Plenary Session "Biotech dealmaking in Europe",Moderator: Dr Fintan Walton, Chairman & CEO, PharmaVentures,Speakers:,Dr Margaret Beer, Director Scientific Liaison, Licensing & External Research Europe, Merck,Christine de los Reyes, Senior Director Licensing & Development, Pfizer,Brian Hargreaves, Global Sector Head, Healthcare, 3i,James Geraghty, Senior Vice President International Development, Genzyme,Dr Helmut Schühsler, Managing Partner, Techno Venture Management
11:45: Company Presentation Sessions (in parallel),21 Biotech CEOs present their business to an audience of international investors and 6 expert reviewers who will lead the Q&A
14:30 - Financial workshops (in parallel),Financing options for biotech companies beyond seed capital,The pro's and con's of various sources of finance. What are the arrays of financing possibilities available to biotech companies? Are some business models better suited to certain financing options than others? When is debt financing possible? Which provide sustainable financing rounds?....,Moderator:,Gordon Duncan, Dunhaw Capital,Speakers:,Brian Kerr, Director Healthcare & Life Sciences Group, Scottish Equity Partners,Carole Nuechterlein, Roche ,Philippe Guinot, Senior Partner, Crédit Lyonnais Private Equity
Cross Continental biotech deals,The different legal systems, registration systems as well as culture brings some unique problems with it. ,Moderator:,Yvonne E. Schlaeppi, Chair, International Practice, Palmer & Dodge LLP ,Speakers:,Hubert Birner, General Partner, Techno Venture Management,Stan Yakatan, Chairman, Katan Associates,Geoff McMillan, Chief Executive, Biofocus
Changing business models,When forced to adapt, how can and do companies make the transition from one business model to another?,Moderator: ,Morris Berrie, Editor in Chief, Biotechnology Investment Today,Speakers: ,Jörn Aldag, President & CEO, Evotec OAI,Raymond Spencer, CFO, Antisoma,Mike Ward, CoFounder & Director, Critical I
15:30 - Company Presentation Sessions (in parallel),21 Biotech CEOs present their business to an audience of international investors and 6 expert reviewers who will lead the Q&A
17:30 : Keynote Speech,David Flores, CEO & President, BioCentury
18:00 - 19:00: One2One meetings,Pre-booked meetings for presenting companies
For more information, please visit http://www.e-unlimited.com/bff(opens in new window)